[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services

This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.

By BioPharma Dive's studioID • Updated May 26, 2026

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.

By BioPharma Dive staff • July 10, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal

An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.

By Ben Fidler • July 8, 2026

Oberland pours up to $400M into MeiraGTx eye gene therapies

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J. 

By Delilah Alvarado • July 7, 2026

Kailera says obesity pill succeeds in late-stage trial in China

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.

By Jonathan Gardner • July 7, 2026

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

By Ben Fidler • July 7, 2026

Vera Therapeutics wins FDA nod for closely watched kidney disease drug

The clearance marks another step forward in treatment for IgA nephropathy and sets up a commercial battle with Otsuka, which brought a similar medication to market last year. 

By Delilah Alvarado • July 7, 2026

Gene editing developer Scribe plots an IPO

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.

By Gwendolyn Wu • July 6, 2026

Novartis to acquire ADC developer in a deal worth up to $1.5B

The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.

By Delilah Alvarado • July 6, 2026

Cancer, immune drugmakers dominate VC funding so far in 2026

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.

By Gwendolyn Wu • July 6, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

A PureTech startup banks $180M for a new IPF drug

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.

By Gwendolyn Wu • July 2, 2026

Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal

The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.

By Kristin Jensen • July 1, 2026

Abivax shares surge as worries subside over immune drug’s cancer risk

According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.

By Jonathan Gardner • July 1, 2026

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.

By BioPharma Dive staff • June 30, 2026

Viridian may have edge over Amgen in eye drug showdown, analysts argue

The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.

By Delilah Alvarado • June 30, 2026

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

By Kelly Bilodeau • June 30, 2026

Beeline ups its Series A round for immune drug work

The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.

By Gwendolyn Wu • June 30, 2026

Theravance, after clinical setbacks, agrees to $929M buyout

The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.

By Jonathan Gardner • June 29, 2026

10 clinical trials to watch in the second half of 2026

The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.

By BioPharma Dive staff • June 29, 2026

FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.

By BioPharma Dive staff • June 26, 2026

At BIO, tension over China biotech deal regulation looms

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.

By Gwendolyn Wu • Updated July 1, 2026

Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.

By Jacob Bell • June 26, 2026

On second try, Acadia drug gets nod from European regulators

The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

By Jonathan Gardner • June 26, 2026

Antares gets $105M from Novartis for new cancer drugs

Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."

By Gwendolyn Wu • June 25, 2026